Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Primary Sjögren syndrome bidirectionally linked to non-Hodgkin lymphoma

23 Sep 2020

A bidirectional relationship is observed between primary Sjögren syndrome (pSS) and non-Hodgkin lymphoma (NHL), reports a nationwide population-based study in Taiwan.

The authors carried out this study to determine whether there existed a bidirectional association between pSS and NHL. They used the National Health Insurance Research Database to identify 15,636 patients with new-onset pSS without previous cancer and 25,074 with new-onset NHL without previous pSS as two nonoverlapping cohorts from 1998 to 2012. Participants were followed until 2013.

Standardized incidence ratios (SIRs) for NHL in patients with pSS and SIR for pSS in those with NHL were compared with the general population.

Of the 15,636 patients with pSS, 741 developed cancers, with 51 cases of NHL. The highest incidence of specific cancer risk in patients with pSS was that for NHL (SIR, 4.6, 95 percent confidence interval [CI], 3.4–6.0). Forty-nine out of 25,074 patients with NHL developed pSS, and the incidence was also elevated (SIR, 3.2, 95 percent CI, 2.4–4.2).

Of note, the highest risk was observed within 1 year after the diagnosis of either pSS or NHL.

“Our findings suggest being alert for patients with pSS or NHL who have early signs of the other disease in clinical care,” the authors said. “The underlying mechanisms of the bidirectional relationship merit further investigation.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.